Lantheus Holdings Inc (LNTH) Q1 2026 Earnings Call Transcript

Why It Matters

Regulatory approvals broaden Lantheus's PET imaging suite, potentially driving long‑term revenue growth, while rising costs and leadership uncertainty could pressure margins in 2026.

Key Takeaways

• Revenue $377.3M, modest 1.2% growth.
• Oncology revenue down 6.5%; PYLARIFY volume up 5.8%.
• DEFINITY holds >80% market share, revenue +6.8%.
• Strategic partnerships revenue +52% driven by MK-6240.
• Operating expenses rise 455 bps, margin pressure persists.

Pulse Analysis

The radio‑diagnostic sector continues to accelerate as hospitals adopt PET imaging for oncology, neurology and cardiology. Lantheus Holdings, with its flagship PSMA PET agent PYLARIFY, remains the market leader, controlling more than 80% of the PSMA‑targeted ultrasound‑enhancing agent DEFINITY market and a strong foothold in beta‑amyloid imaging through NEUROCEQ. The recent FDA approval of PYLARIFY TRUVU, a formulation that enables larger batch sizes at high‑energy cyclotron sites, addresses a key supply‑chain bottleneck and positions Lantheus to serve a broader patient base. This regulatory win reinforces the company’s strategy of focusing on first‑in‑class radio‑diagnostic products.

Financially, Lantheus posted $377.3 million in revenue, a modest 1.2% rise that masks an 8.6% organic increase after stripping out the divested SPEC business. Gross profit margin held steady at 67%, but operating expenses climbed 455 basis points to 32.8% of revenue, driven by the Evergreen and LMI acquisitions and higher R&D spend on late‑stage assets. Despite the expense surge, operating cash flow improved to $125.1 million and free cash flow rose by $23.1 million, underscoring solid cash generation. The surge in strategic‑partnership revenue, up 52%, reflects growing demand for the company’s pharma‑solutions platform, especially MK‑6240.

The pipeline offers multiple catalysts for the next fiscal year. MK‑6240, a Phase 3 tau‑targeted PET tracer for Alzheimer’s, is slated for an August 13 2026 PDUFA decision, while the tentative approval of PNT2003 could add a radiotherapeutic revenue stream once patent stays clear. Lantheus also advances Lantheus 2401, a GRPR‑targeted prostate cancer tracer that could complement its PSMA portfolio. Management reaffirmed 2026 revenue guidance of $1.4‑$1.45 billion and adjusted EPS of $5.00‑$5.25, but noted the upcoming CEO transition as a source of short‑term uncertainty. Investors will watch execution of the PYLARIFY TRUVU rollout and margin trends closely.